As expected, fulvestrant treatment resulted in a significant decrease in proliferation compared to vehicle control, suggesting that PDXOs, like ER+ breast tumors, require ER function to proliferate (Fig. 2d). This evidence concerns the gene ESR1 and breast neoplasm.